SLC2A4 and Hepatic steatosis: As a main component of DZF, berberine has the hypoglycemic, hypolipidemic, and insulin sensitizing effect (Yin et al., 2008; Zhang et al., 2008; Wang et al., 2011; Pirillo and Catapano, 2015), attenuating hepatic steatosis (Sun et al., 2018), and activates AMPK and GLUT4 in the skeletal muscle (Lee et al., 2006).